Major depressive disorder (MDD) is the most common psychiatric illness worldwide, and it displays a striking sex-dependent difference in incidence, with two thirds of MDD patients being women. Ketamine treatment can produce rapid antidepressant effects in MDD patients, effects that are mediated-at least partially-through glutamatergic neurotransmission. Two active metabolites of ketamine, (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-HNK, also appear to play a key role in ketamine's rapid antidepressant effects through the activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. In the present study, we demonstrated that estrogen plus ketamine or estrogen plus active ketamine metabolites displayed additive effects on the induction of the expression of AMPA receptor subunits. In parallel, the expression of estrogen receptor alpha (ERα) was also significantly upregulated. Even more striking, radioligand binding assays demonstrated that [ 3 H]-ketamine can directly bind to ERα (K D : 344.5 ± 13 nM). Furthermore, ketamine and its (2R,6R)-HNK and (2S,6S)-HNK metabolites displayed similar affinity for ERα (IC 50 : 2.31 ± 0.1, 3.40 ± 0.2, and 3.53 ± 0.2 µM, respectively) as determined by [
Introduction
Major depressive disorder (MDD) displays a striking difference in incidence between the sexes, with two thirds of patients being women, which might be due-at least partially-to biological and hormonal factors unique to women [1, 2] . MDD is the most common psychiatric illness worldwide, with an estimated prevalence of approximately 7% in the adult population [3] . The World Health Organization has estimated that depression will be the leading cause of medical disability worldwide by 2020 [4] . Estrogens have both neuroprotective and neuroexcitatory actions and have been recognized as a factor that can influence dopaminergic, serotoninergic, cholinergic and glutamatergic neurotransmission [5] . It has been well-documented that a striking sex difference in the prevalence of MDD begins at age 13 and continues through middle-to-late adulthood [6] [7] [8] [9] . As a result, the incidence of depression increases sharply after puberty [8] and, tragically, suicide is one of the leading causes of death in adolescents as a result of depression, with more than 50% of adolescent suicide victims suffering from depression at the time of death [8] . The etiology of depression remains unclear, but a recent study suggested that sex-specific patterns of glutamate receptor gene expression in MDD patients might contribute to the sex-related pathophysiology of MDD [10] . Specifically, women with MDD displayed higher levels of glutamate receptor expression in the dorsolateral prefrontal cortex as compared to non-depressed women, a pattern that was not seen in men [10] .
Glutamate receptors are included among druggable targets for the treatment of depressive symptoms [11] . For example, ketamine, an antagonist of the N-methyl-D-aspartate (NMDA) receptor, has a very rapid onset of action and is increasingly entering clinical practice for use in the treatment of MDD, especially in patients with treatment resistant depression. Since the first double blind clinical trial designed to assess the antidepressant effects of ketamine in depressed patients was reported in 2000 [12] , a growing body of clinical and preclinical studies has provided evidence in support of ketamine's rapid antidepressant effects [13, 14] . Specifically, ketamine administration, in addition to blocking NMDA receptors, also results in enhanced α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activity as a result of the effect of ketamine and/or its metabolites (2S,6S;2R,6R)-hydroxynorketamine (HNK), actions that might play a role in its rapid antidepressant effects [15] . Furthermore, sex-dependent antidepressant effects have been observed during ketamine treatment, and estrogens have been shown to mediate increased sensitivity to ketamine therapy in rodent models of depression [16] [17] [18] . In addition, (2S,6S;2R,6R)-HNK concentrations were three fold higher in the brains of female than in male mice, which might represent an important factor in the reported sex-dependent difference in the antidepressant effects of ketamine [15] . Similarly, in clinical trials, female subjects had significantly higher plasma levels of (2S,6S;2R,6R)-HNK than did male subjects [19] . A trend toward differences between the sexes in MDD ketamine response has also been reported, but those differences did not reach statistical significance, perhaps as a result of small sample sizes [20] [21] [22] .
CYP2A6 and CYP2B6 are the major enzymes that catalyze ketamine metabolism [23] . Women have higher levels of gene expression and enzyme activity for CYP2A6 and CYP2B6 [24, 25] , both of which are known to be estrogen inducible [26] [27] [28] . Included among the mechanisms by which ketamine might influence MDD is activation of the mTOR signaling pathway, which ultimately increases synaptic protein translation and glutamate ionotropic receptor AMPA subunit 1 (GRIA1) trafficking to the cell membrane [17, 29, 30 ] (see Fig. 1 ).
In the present study, we have performed a series of experiments designed to help increase our understanding of molecular mechanisms responsible for variation in ketamine's therapeutic response. Those experiments focused on estrogen receptor alpha (ERα) and the role of ERα as a transcription factor. The first set of experiments was designed to determine whether estrogen might influence the expression of AMPA receptors, the glutamate receptor type reported to be up-regulated in the brains of depressed women [10] . We also pursued underlying mechanism(s) by which ketamine might be able to interact with ERα, a ligand-activated transcription factor, and, as a result, might influence the transcriptional regulation of genes encoding AMPA receptors as well as CYP2A6 and CYP2B6, genes encoding the major enzymes that catalyze ketamine metabolism. Finally, we tested the possibility that ketamine itself might be an ER ligand-and found that it can bind to ER. As a result, the series of observations reported subsequently provides novel insight into ketamine's molecular mechanisms of action. They also have potential implications for the treatment of MDD with ketamine and/or its active metabolites.
Materials and methods

Cell culture and drug treatment
Human iPSC-derived astrocyte progenitors were cultured and differentiated to mature astrocytes according to the supplier's instructions (Axol Bioscience, Cambridgeshire, UK). U251-MG cells were cultured in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (Cellgro, Manassas, VA, USA) supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch, GA, USA). HepaRG cells were purchased from Biopredic International (Saint Grégoire, France) and were maintained according to the supplier's instructions. Ketamine hydrochloride was purchased from Pfizer (New York, NY, USA). Both (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone hydrochloride (2R,6R-HNK) (lot number: NCGC00378227-18) and (2S,6S)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone hydrochloride (2S,6S-HNK) (lot number: NCGC00373033-12) were synthesized and characterized in Dr. Craig Thomas's laboratory at the National Center for Advancing Ketamine is an NMDA receptor (NMDAR) antagonist and the active ketamine metabolites (2R,6R-HNK and 2S,6S-HNK) also reportedly contribute to antidepressant effects through the activation of AMPA receptors (AMPRs). Ketamine induces glutamate release. Glutamate in turn binds to AMPARs to induce depolarization as well as sodium (Na 2+ ) and calcium (Ca
2+
) influx through the AMPA receptors and Ltype voltage gated calcium channels (VDCCs), respectively. This results in increased brain-derived neurotropic factor (BDNF) release from synaptic vesicles. BDNF binds to tyrosine kinase receptor B (TrkB) with high affinity, which leads to activation of both the ERK and AKT/mTOR pathways, increasing synaptic protein translation and GRIA1 trafficking to the cell membrane.
Translational Sciences (Rockville, MD, USA). Cells were treated with ketamine or with the ketamine metabolites (2R,6R)-HNK or (2S,6S)-HNK for 24 h in serum and phenol red-free medium. In some experiments, cells were exposed to estradiol (E2) (Sigma, St. Louis, MO, USA) or fulvestant (Sigma, St. Louis, MO, USA) together with ketamine, (2R,6R)-HNK or (2S,6S)-HNK, at concentrations similar to plasma concentrations observed during ketamine therapy [19] .
RNA isolation and quantitative real time PCR (qRT-PCR)
Total RNA was extracted using the Quick-RNA™ MiniPrep kit (Zymo, Irvine, CA, USA). The PCR reaction contained 100 ng of total RNA, 5 µl of VeriQuest 2X SYBR Green One-Step qRT-PCR master mix (Affymetrix, Santa Clara, CA USA), 1 µl of gene specific primers (Table 1) , 0.1 µl of VeriQuest 100X RT enzyme mix and distilled water up to 10 µl per reaction. The expression of ESR1, CYP2A6 and CYP2B6 was quantified using TaqMan gene expression assays (Life Technologies, Carlsbad, CA, USA). qRT-PCR reactions were performed in duplicate using the Applied Biosystems ViiA 7™ Real-Time PCR System (Life Technologies, Carlsbad, CA, USA). The 2 −ΔΔCt method was employed for statistical analysis.
Cloning of promoter reporter gene constructs for CYP2A6 and CYP2B6
The promoter sequences of CYP2A6 and CYP2B6 were PCR amplified using genomic DNA extracted from human lymphoblastoid cell lines. The amplified PCR products (2481 bp and 1845 bp) for the CYP2A6 and CYP2B6 promoters, respectively, were cloned into the Nhel and Sal1 sites of the pGL3 basic plasmid to create pGL3-promoter constructs for CYP2A6 and CYP2B6. PCR primer sequences for the CYP2A6 and CYP2B6 promoters are listed in Table 1 . The sequences of the constructs were verified by Sanger sequencing.
Luciferase reporter gene assays
U251-MG cells were used to perform luciferase reporter gene assays. Cells (1 × 10 5 ) were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with 1 µg of the plasmid DNA and 100 ng of pRL-SV40 Renilla luciferase reporter as an internal control (Promega, Madion, WI, USA) in a 6-well plate. After 24 h, the cells were treated with increasing concentrations of ketamine, (2R,6R)-HNK or (2S,6S)-HNK for 24 h. Luciferase assays were performed using a dual-luciferase reporter assay system (Promega, Madison, WI, USA). Renilla activity was used to correct for possible variation in transfection efficiency. The pGL3 basic vector without insert was used as a negative control. Expression was calculated as the relative firefly luciferase activity normalized by use of the activity of the transfection control, Renilla luciferase. Results are presented as fold change in relative luciferase units as compared to the pGL3 basic vector. All experiments were repeated three times in triplicate.
ERE luciferase reporter assays
U251-MG cells (1 × 10 5 ) were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with ERE responsive firefly luciferase reporter constructs (Qiagen, Valenicia, CA, USA). Twenty four hours after transfection, the cells were treated for an additional 24 h with increasing concentrations of ketamine, (2R,6R)-HNK or (2S,6S)-HNK. Luciferase assays were then performed with the Dual-Luciferase Reporter assay system (Promega, Madison, WI, USA). Relative luciferase activities were normalized to Renilla luciferase activities. Results were presented as fold change in relative luciferase units compared with vehicle treatment. All experiments were performed at least three times in triplicate.
ERα ligand binding assays
Recombinant full length human estrogen receptor alpha (ESR1-1033H, Creative BioMart, NY, USA) was used to perform radioligand binding assays and surface plasmon resonance (SPR). For the radioligand binding assays, protein was diluted in ice-cold assay buffer (10 mM Tris-HCl; 1 mM EDTA; 1 mM EGTA; 1 mM NaVO3; 1% glycerol; 0.25 mM leupeptin; 1% BSA; 1 mM DTT). Estradiol- [2, 4, 6, H (N) To determine nonspecific binding, a 500-fold excess of non-radioactive ligand, i.e. 500 nM E2, was incubated overnight together with 0.75 nM ER protein and radioactive ligand, i.e. 1 nM Estradiol- [6, H(N)] at 4°C. Bound and unbound estradiol were separated by incubation with ice-cold dextran-coated charcoal (DCC) on ice for 10 min. After centrifugation for 15 mins at 8000 rpm, 100 µl of DCC suspension was gently transferred into LSC vials containing 1 ml Ultima Gold scintillation cocktail (Perkin Elmer Life Sciences, Boston, MA, USA). Radioactivity was then measured using a Beckmann LS 6500 liquid scintillation counter (Ramsey, MN, USA). Specific binding (SB) was calculated by subtracting the value for NSB from that for TB. The equilibrium dissociation constant for the radioligand (K D ) was calculated using non-linear regression analysis (GraphPad Prism Software v7, San Diego, CA, USA). 
Surface plasmon resonance (SPR)
We performed NTA mixed capture of His 6 -tagged hERα (ESR1-1033H, Creative BioMart, NY, USA) using a Biacore T200 surface plasmon resonance (SPR) analyzer (GE Healthcare). Binding of ketamine to ERα was detectable by this method, which an equilibrium dissociation constant (K D ) of 215 ± 100 nM. Briefly, the NTA chip (BR-1000-34) was conditioned with 350 mM EDTA (pH 8.3) for 1 min followed by washing with immobilization buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.01% (w/w) Polysorbate) for 5 min at a flow 30 µl/min. After a 0.5 mM NiCl 2 injection (60 s), the His 6 -tagged hERα protein (0.2 mg/ml) was captured at a flow of 5 μl/min. Additionally, after capture, the ligand was cross-linked using amine coupling with a 1 min pulse of N-ethyl-N′- [dimethylaminopropyl] carbodiimide/N-hydroxysuccinimide) and ethanolamine, and reached a level of 11000-12000 resonance units (RU). Ketamine in calcium-and magnesium-free Dulbecco's phosphate buffered saline containing 0.01% (w/w) Polysorbate was run over the chip with a flow of 50 µl/min for 30 s and allowed to dissociate for 60 s. Kinetic analysis of SPR data was performed using BiaEvaluation (GE). Sensograms were subtracted for background contributions, and affinity constants were derived using a steady state affinity fitting 1:1 interaction model.
Immunofluorescence staining and confocal imaging analysis
U251-MG cells were grown on glass coverslips and treated with E2 0.1 nM or ketamine or the two active ketamine metabolites (400 nM) for 24 h. Cells were then fixed in 4% paraformaldehyde at room temperature for 10 min. Cells were washed in cold PBS and permeablized with 0.2% Triton X-100 in PBS. After blocking for one hour with 3% BSA, cells were incubated with mouse anti-ESR1 antibody (Santa Cruz Biotechnology, Dallas, Texas, USA) overnight at 4°C. The secondary antibody (red) was ab150119 Alexa Fluor® 647 goat anti-mouse IgG (H + L) used at 1:1000 dilution for an hour. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43 µM. Slides were visualized using fluorescence microscopy (Olympus, FV1200).
Statistics
GraphPad Prism Software v7 (San Diego, CA, USA) was used for data analysis. Results were presented as mean ± S.E.M. Gene expression and luciferase activities were analyzed using One-way or two-way ANOVA, followed by Tukey's multiple comparison tests for individual comparisons when significant effects were detected. Differences were considered significant at p < 0.05.
Results
Estrogens and ketamine act additively to induce AMPA receptor mRNA expression
As a first step in this series of experiments, the mRNA expression of AMPA receptors in U251-MG cells was determined after exposure of the cells to estradiol (E2), ketamine, (2R,6R)-HNK or (2S,6S)-HNK-either alone or together. The concentrations of E2, ketamine and ketamine metabolites used to perform these experiments were selected to fall within the physiological range for E2 and within the range of concentrations of ketamine and ketamine metabolites observed during ketamine infusion therapy for patients with depression [19, 31] . As shown graphically in Fig. 2A, E2 induced the expression of the GRIA1, GRIA2 and GRIA4 AMPA receptor subunits by approximately 2 fold in a dose-dependent fashion. In similar fashion, ketamine exposure induced mRNA expression of the same AMPA receptor subunit genes, GRIA1, GRIA2 and GRIA4, approximately 1.5-2 fold in these cells (Fig. 2B) . However, GR1A3 mRNA expression was not altered significantly in response to either E2 or ketamine treatment. The expression of GRIA1, GRIA2 and GRIA4 responded in a fashion very similar to the response to E2 when the cells were exposed to ketamine and to the ketamine metabolites (2R,6R)-HNK and (2S,6S)-HNK (Fig. 2B )-at concentrations that are observed in vivo during ketamine infusion therapy [19] . Strikingly, the addition of E2 at physiologic concentrations was additive to the effect of ketamine on GRIA1, GRIA2 and GRIA4 mRNA expression (Fig. 2B) . However, this additive effect was only observed at 0.1 nM E2 together with 400 nM ketamine. Similarly, E2 exposure together with the ketamine metabolites (2R,6R)-HNK or (2S,6S)-HNK also displayed an additive effect on the induction of AMPA receptor subunits, once again with the exception of GRIA3 (Fig. 2B) . Similar results with regard to E2 plus ketamine or ketamine metabolites resulting in the induction of AMPA receptor subunit mRNA expression were observed when we conducted experiments using primary human astrocytes (Fig. 3) . The majority of MDD patients are women, so our results raised the possibility that these E2-based effects might contribute to ketamine treatment response in women [19] . As the next step in this series of studies, we set out to determine whether ERα-a ligand-activated transcription factor-might play a role in response to ketamine treatment. We found that ketamine and its active metabolites significantly increased ERα expression in a concentration-dependent fashion (Fig. 4A) and, even more striking, that E2 acted additively with ketamine to further induce ERα expression (Fig. 4A ). These observations were paralleled by the results of estrogen response element (ERE) luciferase reporter assays (Fig. 4B ). This series of findings led us to ask whether ketamine and its metabolites might induce the expression of the two CYP isoforms that are known to catalyze the formation of the ketamine metabolites, CYP2A6 and CY2B6 [23] , both of which are known to be estrogen inducible as a consequence of functional EREs located in their promoters [26] [27] [28] .
CYP2A6 and CYP2B6 induction by ketamine and its metabolites
Based on observations described in preceding paragraphs, we considered the possibility that the expression of CYP2A6 and CYP2B6 might also be induced by ketamine and its metabolites. CYP2A6 and CYP2B6 are not highly expressed in the brain. Therefore, we created reporter constructs for these two genes that included the functional EREs present in their promoters, as shown schematically in Fig. 5A . Consistent with previous reports [26] [27] [28] , E2 induced transcriptional activity for both the CYP2A6 and CYP2B6 constructs (Fig. 5B) . In addition ketamine, (2R,6R)-HNK and (2S,6S)-HNK could also induce transcriptional activity for both the CYP2A6 and CYP2B6 promoter constructs. Even more striking, this induction could be further enhanced by E2 exposure after expression in both U251-MG and HepaRG cells (Fig. 5C and D) .
These observations were confirmed when gene expression studies were performed with human astrocytes (Fig. 6A) , and with HepaRG cells (Fig. 6B) , liver-derived cells that highly express CYP2A6 and CYP2B6. Surprisingly, induction of the expression of CYP2A6 and CYP2B6-both of which are known to be induced by estrogens-was also observed in the absence of estrogens in response to treatment with ketamine and the ketamine metabolites, (2R,6R)-HNK and (2S,6S)-HNK ( Fig. 6A and B) .
Induction of CYP2A6, CYP2B6 and AMPA receptors by ketamine is lost after ER blockade
To provide further evidence that the induction of CYP2A6 and CYP2B6 expression was mediated by ERα, we examined the impact of ERα knockdown on this induction. The induction of CYP2A6 and CYP2B6 mRNA expression by ketamine was lost after ERα was silenced by siRNA knockdown (Fig. 7A ). In addition, (2R,6R)-HNK and (2S,6S)-HNK also failed to induce the expression of CYP2A6 and CYP2B6 after ERα knockdown. Similar results were observed when ERα signaling was inhibited using fulvestant (ICI)-an ER blocker (Fig. 7B) . Furthermore, ketamine, (2R,6R)-HNK and (2S,6S)-HNK all failed to induce the expression of GRIA1, GRIA2 and GRIA4 when ERα was knocked down (Fig. 8 ) or silenced pharmacologically (Fig. 9) . In contrast, all three of these AMPA receptor subunit genes could be induced by E2 and by ketamine and its metabolites when ERα was present, as shown in Fig. 2 . Taken as a whole, these results indicated that ERα can play an important role in the transcriptional effects of ketamine and the two ketamine metabolites, i.e., in the induction of the expression of CYP2A6 and CYP2B6 by ketamine and by (2R,6R)-HNK or (2S,6S)-HNK. They also raised the possibility that ketamine and its two active metabolites might either enhance ERα binding to EREs through an unknown mechanism or that they might themselves be ER ligands.
Ketamine, (2R,6R)-HNK and (2R,6R)-HNK as novel ERα ligands
We next set out to test the hypothesis that ketamine might bind directly to ERα. In initial experiments, we examined the ability of ketamine to bind to ERα using SPR, a biophysical technique that detects interactions between an immobilized protein and a ligand in solution. As indicated in Fig. 10 , binding of ketamine to ERα was readily detectable by this method, with an equilibrium dissociation constant (K D ) of 215 ± 100 nM. Using a more sensitive and more physiological approach, we also performed radioligand binding assays. When the amount of radioactive ligand bound to ERα protein was assessed at nine different concentrations of [ 3 H]-ketamine (range 4 nM-400 nM) [ 3 H]-ketamine bound to ERα with a K D = 344 ± 13 nM based on non-linear regression analysis of the saturation binding assay (Fig. 11A) . We also performed [ (Fig. 11B ). These observations suggested that ketamine and its' two active metabolites were most likely binding to the same site on ERα. However, E2 was unable to displace bound [ 3 H]-ketamine, indicating that ketamine might bind to ERα at a novel site different from the estradiol binding site and, as a result, E2 was ineffective in displacing [ 3 H]-ketamine binding (Fig. 11B) . To further explore that possibility, we also performed (Fig. 12B) . Finally, to complement and extend our studies of the potential functional effects of ketamine on ERα as demonstrated by the luciferase reporter gene assay results shown graphically in Fig. 5 , we performed immunofluorescence studies of U251-MG cells after exposure to E2, to ketamine or to the two ketamine active metabolites. Just as exposure to E2 resulted in nuclear translocation of ERα, so too did exposure to ketamine or its active metabolites (Fig. 13) .
Discussion
Ketamine, a novel and highly promising drug for the treatment of MDD, has a very rapid onset of action [13] . In particular, MDD patients and experimental animal models for MDD both display rapid antidepressant response within hours after ketamine administration [20] [21] [22] . Ketamine is known to be an NMDA receptor antagonist. However, a recent study suggested that the antidepressant effect of the two major ketamine active metabolites (2S,6S;2R,6R)-hydroxynorketamine (HNK) depends on the activation of AMPA receptors [15] . In that study, (2S,6S;2R,6R)-HNK were essential for ketamine's antidepressant effects, but (2R,6R)-HNK lacked some ketamine-related side effects [15] . In addition, several preclinical studies have reported sex-related differences in the antidepressant effect of ketamine. In particular, females displayed greater sensitivity to ketamine than males in rodent models of depression [16] [17] [18] . However, the mechanism(s) underlying this sex-related enhanced sensitivity to ketamine in female rodent models has remained unclear.
In the present study, we set out to determine whether estrogen might play a role in regulation of the expression of the glutamate receptors that are among the therapeutic targets for ketamine in the treatment of MDD. We chose to perform these studies using U251-MG cells, cells derived from an astrocytoma, which resulted in data comparable with results generated using primary human astrocytes (Figs. 3  and 6 ). Use of this cell line also made it possible for us to subsequently pursue functional genomic studies, which would have been impractical using primary astrocytes due to their high cost and the lengthy time required for differentiation. Our results indicated that E2 could induce the expression of three of the four AMPA subunits. We also found that ketamine and the active ketamine metabolites (2R,6R)-HNK and (2S,6S)-HNK behaved in a similar fashion. Specifically, all three Fig. 9 . Induction of the expression of GRIA1, GRIA2 and GRIA4 by ketamine and ketamine metabolites was lost after ERα blockade by fulvestant (ICI). Specifically, the expression of AMPA receptors is known to be enhanced in response to ketamine therapy. However, we observed that GRIA1, GRIA2 and GRIA4 were not induced by increasing concentrations of ketamine or its metabolites (100, 200, 400 nM) after ER blockade. Values shown are mean +/-SEM of three independent determinations. compounds could induce the mRNA expression of CYP2B6 and CYP2A6 in cell lines obtained from both brain and liver (Fig. 6 ). (2S,6S)-HNK and (2R,6R)-HNK are the major HNK metabolites found in the plasma of both humans and mice; and both of these metabolites are being considered as possible next generation rapid acting antidepressant agents [15, 32] . It should also be pointed out that female subjects who received ketamine infusion therapy appeared to have higher concentrations of these active ketamine metabolites than did male subjects [19] , which might have occurred, in part, because females had higher expression and activity of CYP2A6 and CYP2B6 [26] [27] [28] and because the formation of (2S,6S;2R,6R)-HNK results from biotransformation catalyzed primarily by these two CYP enzymes [23] , enzymes that are known to be estrogen inducible [26] . These observations led us to ask whether ketamine and the two ketamine metabolites might-like E2-be ER ligands. Our radioligand binding and SPR studies showed that all three compounds bound to ERα-although the site of binding remains unclear. Further studies such as protein-ligand docking will be needed to determine the position and orientation of their binding to ERα. The present study used a variety of cell lines to perform functional genomic studies. However, each of those cell lines has limitations. Therefore, our observations will have to be replicated by future studies conducted with clinical samples and/or with cell lines derived from patients, i.e, iPS cells. However, the present results represent a potentially important step in the process of obtaining functional insight into mechanism of action for ketamine and its active metabolites, and the present study is the first to demonstrate the binding of ketamine and its active metabolites to ERα. Ketamine and the two major ketamine metabolites that we studied were all able to regulate the expression of ESR1, the gene that encodes ERα (Fig. 4A) , as well as the genes encoding three of the four AMPA receptor subunits and CYP2A6 and (Fig. 11) . Therefore, ketamine and the ketamine metabolites (2R,6R)-HNK and (2S,6S)-HNK appear to be novel ERα ligands, although the site to which they bind remains unclear. These results also suggested the existence of a positive feedback loop by which estrogen can augment the effects of ketamine and its (2R,6R)-HNK and (2S,6S)-HNK metabolites on the transcription of ERα (Fig. 4A) . We also found that ERα intracellular localization was altered when cells were exposed to ER ligands, in this case E2, or ketamine and its two active metabolites (Fig. 13) . Specifically, when cells were treated with E2, or ketamine or its metabolites, ERα trafficked from the cytoplasm to the nucleus where it acts as a ligand activated transcription factor. Both CYP2A6 and CYP2B6 can be induced by E2, in part, due to functional estrogen response elements (EREs) in their promoter regions, which could interact with ERα and result in transcription regulation, consistent with previous reports [26] [27] [28] . The present study demonstrated that knockdown of ERα resulted in downregulation of the expression of AMPA receptors, and the induction of AMPA expression by E2 or ketamine treatment was lost (Fig. 8) . Future studies are warranted to determine molecular mechanisms underlying the additive effects on AMPA expression of ketamine plus E2 treatment.
Given the interaction of ketamine and its metabolites with ERα, one question is whether there may be any potential concerns relating to estrogen-related cancers. It is known that endogenous estrogen levels are directly associated with risk for developing breast cancer [33] . The use of estrogens in the treatment of infertility has been associated with an increased risk of breast cancer but only if the women achieved a 10+ week pregnancy [34] , which may be a potential reason to avoid pregnancies in women receiving ketamine. In the placebo-controlled Women's Health Initiative Study of unopposed conjugated equine estrogens in menopausal women without a uterus, there was a decrease in the incidence of breast cancer [35] . The main issue with unopposed estrogens appears to be the risk for endometrial cancer [36] , which might indicate that monitoring postmenopausal women treated with ketamine for endometrial abnormalities would be prudent.
In conclusion, two thirds of MDD patients are women, which might be due, at least in part, to biological and hormonal factors unique to women. Estrogens can cross the blood brain barrier and interact with cells in the central nervous system. ERα is a ligand-activated transcription factor, and reduced ERα mRNA expression was previously reported in the basomedial nucleus of the amygdala in patients with MDD [37] . The present study is the first to identify ketamine and its metabolites (2R,6R)-HNK and (2S,6S)-HNK as possible novel ERα ligands. Our results also showed that estrogens and ketamine can act in an additive fashion to induce the expression of three of the four AMPA receptor subunits, and it has been reported that these receptors may play a major role in the antidepressant effects of ketamine. Finally, silencing of ERα blocked induction of the expression of genes encoding CYP2A6, CYP2B6 and three of the four AMPA receptor subunits. This series of observations highlight(s) the possible role that ERα may play in the transcriptional effects of ketamine and the two major ketamine active metabolites, thus contributing to ketamine therapeutic response in major depressive disorder (MDD)-a disease for which two thirds of patients are women.
number: NCGC00378227-18) and (2S,6S)-hydroxynorketamine (lot number: NCGC00373033-12) were synthesized and characterized in Dr Craig Thomas's laboratory at the National Center for Advancing Translational Sciences. We thank Dr. Thomas and his team for these compounds. This work was supported in part by National Institutes of Health grants U19 GM61388 (the Pharmacogenomics Research Network -PGRN), P50 CA11620, RO1 CA196648, RO1 GM28157, RO1 MH108348, U54 GM114838 and RO1 CA138461.
Disclosure
Drs. Richard Weinshilboum and Liewei Wang are co-founders and stockholders in OneOme, a pharmacogenomics decision support company.
